Results 101 to 110 of about 35,349,291 (244)

Development of selective non-peptide angiotensin II type 2 receptor agonsists

, 2010
The development of the first drug-like selective angiotensin II type 2 (AT(2)) receptor agonist (22) derived from the non-selective angiotensin II type 1 (AT(1)) receptor/AT(2) receptor agonist L-162,313 is presented.
Mathias Alterman, Alterman, Mathias,
core   +1 more source

Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson's disease

Neurobiology of Disease, 2013
The mechanism by which estrogen protects dopaminergic neurons has not yet been clarified. It is not known if changes in RhoA/Rho kinase activity are involved in the enhanced vulnerability of dopaminergic neurons observed after estrogen depletion.
Ana I. Rodriguez-Perez, Antonio Dominguez-Meijide, Jose L. Lanciego, Maria J. Guerra, Jose L. Labandeira-Garcia   +4 more
doaj   +1 more source

Clinical Impact of Adherence to Fractional Flow Reserve Guidance in Acute Coronary Syndrome

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Fractional flow reserve (FFR) is established to guide revascularization in stable coronary disease and non‐culprit lesions in acute coronary syndromes (ACS). However, real‐world adherence to FFR guidance across the spectrum of ACS presentations, including ambiguous culprit scenarios, remains incompletely characterized.
Eun Ho Choo, Ik Jun Choi, Sungmin Lim, Donggyu Moon, Dae‐Won Kim, Kiyuk Chang   +5 more
wiley   +1 more source

NAFLD‐related hepatocellular carcinoma: The growing challenge

Hepatology, EarlyView., 2022
Risk and protective factors for NAFLD‐related hepatocellular carcinoma Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially.
Pir Ahmad Shah, Rashmee Patil, Stephen A. Harrison   +2 more
wiley   +1 more source

Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis

, 2009
Angiotensin type 1 (AT 1 ) receptor blocker (ARB) ameliorates progression of chronic kidney disease. Whether this protection is due solely to blockade of AT 1 , or whether diversion of angiotensin II from the AT 1 to the available AT 2 receptor, thus ...
Ma, Li-Jun, Tang, Yiwei, Zuo, Yiqin, Yang, Haichun, Han, Jee Young, Kon, Valentina, Naito, Takashi, Fogo, Agnes B.   +7 more
core   +1 more source

Rosiglitazone, a Ligand to PPARγ, Improves Blood Pressure and Vascular Function through Renin-Angiotensin System Regulation

PPAR Research, 2019
Rosiglitazone (RGZ), a peroxisome proliferator-activated receptor gamma (PPARγ) ligand, has been reported to act as insulin sensitizer and exert cardiovascular actions.
María Sánchez-Aguilar, Luz Ibarra-Lara, Leonardo Del Valle-Mondragón, María Esther Rubio-Ruiz, Alicia G. Aguilar-Navarro, Absalom Zamorano-Carrillo, Margarita del Carmen Ramírez-Ortega, Gustavo Pastelín-Hernández, Alicia Sánchez-Mendoza   +8 more
doaj   +1 more source

Baseline Body Mass Index Category and Incident Treated Hypertension in Australian Men: A Linked Prospective Cohort Study Using PBS/MBS Data

Chronic Diseases and Translational Medicine, EarlyView.
Kaplan–Meier hypertension‐free survival by baseline body mass index category, primary adult cohort (men aged ≥ 18 years, n = 12,742). Time since baseline in years is plotted on the horizontal axis and the probability of remaining free of treated hypertension is plotted on the vertical axis. Numbers at risk are shown beneath the plot.
Ebenezer Afrifa‐Yamoah
wiley   +1 more source

Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes

, 2011
Artavazd Tadevosyan1, Eric J MacLaughlin2, Vardan T Karamyan31Departments of Medicine, Montreal Heart Institute and Université de Montréal, Montreal, QC, Canada; 2Department of Pharmacy Practice, 3Department of Pharmaceutical ...
Eric J MacLaughlin, Artavazd Tadevosyan, Vardan T Karamyan   +2 more
core  

Osteoprotegerin: a pancreatic islets dysfunction and vascular injury modulator [PDF]

, 2011
Background. Osteoprotegerin (OPG) is a soluble glycoprotein of the tumor necrosis factor (TNF) receptor superfamily, which was initially identified as a key regulator in bone turnover.
Toffoli, Barbara
core  

Imidazole-Based AT₁ Receptor Ligands: Design, Synthesis and Pharmacological Evaluation

Molecules
The angiotensin II type 1 (AT1) receptor is a key component of the renin–angiotensin system (RAS) and a validated target for cardiovascular and renal disorders. Developing small molecules with defined AT1 versus AT2 binding profiles remains important for
Florian Descamps, Marouane Rami, Jean-François Goossens, Patricia Melnyk, Maxime Liberelle, Saïd Yous   +5 more
doaj   +1 more source